Victory Capital Management
UTHR icon

Victory Capital Management’s United Therapeutics UTHR Stock Holding History

Victory Capital Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$35.9M Sell
60,541
-167,842
-73% -$83.6M 0.02% 664
2025
Q4 		$111M Buy
228,383
+118,628
+108% +$55.2M 0.06% 281
2025
Q3 		$46M Sell
109,755
-286,900
-72% -$96.5M 0.03% 588
2025
Q2 		$114M Buy
396,655
+150,296
+61% +$44.9M 0.07% 263
2025
Q1 		$75.9M Buy
246,359
+52,951
+27% +$18.1M 0.08% 306
2024
Q4 		$68.2M Buy
193,408
+6,589
+4% +$2.42M 0.07% 344
2024
Q3 		$66.9M Buy
186,819
+33,599
+22% +$11.3M 0.06% 372
2024
Q2 		$48.8M Buy
153,220
+8,116
+6% +$2.15M 0.05% 455
2024
Q1 		$33.3M Buy
145,104
+10,942
+8% +$2.47M 0.03% 626
2023
Q4 		$29.5M Buy
134,162
+101,419
+310% +$23.4M 0.03% 631
2023
Q3 		$7.4M Buy
32,743
+10,140
+45% +$2.34M 0.01% 1125
2023
Q2 		$4.99M Sell
22,603
-5,958
-21% -$1.32M 0.01% 1206
2023
Q1 		$6.4M Sell
28,561
-110
-0.4% -$27.1K 0.01% 1155
2022
Q4 		$7.97M Buy
28,671
+7,046
+33% +$1.78M 0.01% 1093
2022
Q3 		$4.53M Buy
21,625
+5,693
+36% +$1.27M 0.01% 1270
2022
Q2 		$3.75M Buy
15,932
+58
+0.4% +$11.8K ﹤0.01% 1307
2022
Q1 		$2.82M Buy
15,874
+3,901
+33% +$743K ﹤0.01% 1399
2021
Q4 		$2.59M Sell
11,973
-499
-4% -$98K ﹤0.01% 1477
2021
Q3 		$2.3M Sell
12,472
-863
-6% -$170K ﹤0.01% 1558
2021
Q2 		$2.39M Sell
13,335
-1,817
-12% -$346K ﹤0.01% 1579
2021
Q1 		$2.53M Sell
15,152
-646
-4% -$108K ﹤0.01% 1578
2020
Q4 		$2.4M Sell
15,798
-4,433
-22% -$582K ﹤0.01% 1468
2020
Q3 		$2.04M Sell
20,231
-366
-2% -$40.2K ﹤0.01% 1436
2020
Q2 		$2.49M Sell
20,597
-24,711
-55% -$2.78M ﹤0.01% 1366
2020
Q1 		$4.3M Buy
45,308
+34,815
+332% +$3.31M ﹤0.01% 1314
2019
Q4 		$924K Buy
10,493
+304
+3% +$26.8K ﹤0.01% 1778
2019
Q3 		$813K Sell
10,189
-22,439
-69% -$1.81M ﹤0.01% 1741
2019
Q2 		$2.55M Buy
32,628
+9,266
+40% +$866K 0.01% 1079
2019
Q1 		$2.74M Buy
23,362
+1,425
+6% +$166K 0.01% 1016
2018
Q4 		$2.39M Sell
21,937
-84
-0.4% -$9.74K 0.01% 994
2018
Q3 		$2.82M Buy
+22,021
New +$2.72M 0.01% 1024
2017
Q3 		– Sell
-6,549
Closed -$850K – 1874
2017
Q2 		$850K Buy
6,549
+1,133
+21% +$141K ﹤0.01% 1223
2017
Q1 		$733K Buy
5,416
+432
+9% +$65.4K ﹤0.01% 1238
2016
Q4 		$715K Buy
4,984
+589
+13% +$75.2K ﹤0.01% 1209
2016
Q3 		$519K Buy
+4,395
New +$528K ﹤0.01% 1242

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Victory Capital Management's UTHR Position: Q1 2026 in Review

Victory Capital Management reduced its United Therapeutics (UTHR) stake by 73% in Q1 2026, selling an estimated $83.6M and leaving 60,541 shares worth $35.9M. The position accounts for 0.02% of the portfolio, ranked #664.

Victory Capital Management first reported a position in UTHR in Q3 2016 and has held it in 35 quarters since. The position peaked at $114M in Q2 2025. 851 funds tracked by Wall St. Rank hold UTHR as of Q1 2026.

  • Victory Capital Management held 60,541 shares of United Therapeutics worth $35.9M as of Q1 2026.
  • Victory Capital Management sold 167,842 United Therapeutics shares in Q1 2026, an estimated $83.6M.
  • United Therapeutics made up 0.02% of Victory Capital Management's portfolio in Q1 2026, its #664 holding.
  • Victory Capital Management first reported a position in United Therapeutics in Q3 2016 and has held it in 35 quarters since.
  • Victory Capital Management's United Therapeutics position peaked at $114M in Q2 2025.
  • 851 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2026.

Based on Victory Capital Management's 13F filing for Q1 2026, filed 15 May 2026.